Table 1 Different types of EBV vaccine studies.
From: Urgency and necessity of Epstein-Barr virus prophylactic vaccines
Types | Antigen | Formulation | Ref. |
|---|---|---|---|
Subunit vaccine | gp350 | Subunit gp350 adjuvanted with Freund’s adjuvant or alum | |
Subunit gp350 adjuvanted with Alum | |||
Subunit gp350 adjuvanted with GLA/SE | |||
Subunit gp350 adjuvanted with ISCOMs | |||
Subunit gp350 adjuvanted with SAF-1 or alum | |||
Subunit gp350 adjuvanted with SAF-1 | |||
gp350 incorporated into liposomes | |||
Tetrameric and monomeric gp3501–470 + CpG and alum | |||
Fc-gp350 adjuvanted with CpG OND/Alum | |||
gB | Trimeric gB adjuvanted with CpG and alum | ||
gH/gL | Trimeric and monomeric gH/gL adjuvanted with CpG and alum | ||
/ | Glycoprotein complex | ||
EBNA-1 | αDEC-205-EBNA-1 adjuvanted with poly(I:C) | ||
Epitope vaccine | gp350 | CTL epitopes of gp350 and gH adjuvanted with TT and IFA | |
DC vaccine | BZLF-1 | DCs transfected to express BZLF-1 | |
DNA vaccine | gp350 | pCDNA3.1 plasmid encoding gp350 | |
gp350 | plasmid of tetrameric gp3501–470 | ||
mRNA vaccine | gH/gL/gp220/gp42 | mRNA-1189 (NCT05164094) | / |
Nanoparticle vaccine | gH/gL/gp42 | ferritin-gH/gL/gp42 + SAS | |
gH/gL | ferritin-gH/gL + SAS | ||
nanoparticle displaying 60 copies of gH/gL | |||
gp350 | ferritin-gp350 + SAS | ||
gp350 | LS- or I3-01- gp350 domain I/II/III adjuvanted with MF59 | ||
Virus-like particles (VLPs) | / | EBV-VLPs deleted EBNA-2, LMP-1, EBNA-3A, -B, -C and BZLF-1 | |
/ | EBV-VLPs deleted BFLF-1/BFRF-1A or BBRF-1 | ||
gp350/gB/gp42/gH/gL | NDV-VLPs-gp350, gB, gp42, gH and gL | ||
gH/gL/EBNA-1 | NDV-VLPs-gH/gL-EBNA-1 | ||
gB/LMP-2 | NDV-VLPs- gB-LMP-2 | ||
gp350 | NDV-VLPs-gp350 | ||
HBc149 displaying immunodominant epitopes of gp350 | |||
EBNA-1 | Immunogenic particles containing EBNA-1 + poly (I: C) | ||
Viral vector vaccines | gp350 | VV expressing gp350 | |
Adv expressing gp350 | |||
gp350/gB/EBNA-2 or EBNA-3C | VV expressing gp350, gB, EBNA-2, or EBNA-3C | ||
EBNA-1 | Adv expressing EBNA-1 and VV-EBNA-1 |
